TG Therapeutics, Inc. (TGTX): TG Therapeutics' CEO Discusses Q3 2013 Results ... Seeking Alpha The third preclinical poster will demonstrate the activity of 1202 in Hodgkin's lymphoma cell lines as a single agent as well as in combination with rituximab and anti-CD 30 conjugated monoclonal antibody approved for patients with Hodgkin's lymphoma ... |
